Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 1;9(1):e49.
doi: 10.1002/vro2.49. eCollection 2022 Dec.

Randomised trial evaluating chemotherapy alone or chemotherapy and a novel monoclonal antibody for canine T-cell lymphoma: A multicentre US study

Margaret L Musser  1 , Craig A Clifford  2 , Philip J Bergman  3 , Laura S Treml  4 , Lydia C Cook McAnulty  5 , Elizabeth A McNiel  6 , Chad M Johannes  7
Affiliations

Randomised trial evaluating chemotherapy alone or chemotherapy and a novel monoclonal antibody for canine T-cell lymphoma: A multicentre US study

Margaret L Musser et al. Vet Rec Open. .

Abstract

Background: Canine peripheral nodal T-cell lymphoma is considered chemotherapy resistant and carries a relatively poor prognosis. Prospective evaluations reporting the impact of chemotherapy on progression-free survival (PFS) and overall survival time for dogs with T-cell lymphoma are lacking. This study examined the impact of L-CHOP (L-asparaginase, doxorubicin, cyclophosphamide, vincristine, prednisone) chemotherapy or L-CHOP in combination with AT-005, a US Department of Agriculture-licensed caninised monoclonal antibody, on PFS and response rates in dogs with clinical intermediate- and high-grade peripheral nodal T-cell lymphoma.

Methods: A prospective, randomised, placebo-controlled, investigator- and owner-blinded, multicentre study was completed. All dogs received a 19-week L-CHOP chemotherapy protocol with randomisation (1:1) into placebo or AT-005 groups. Response was evaluated via the Veterinary Cooperative Oncology Group criteria for canine lymphoma.

Results: Forty-nine dogs were enrolled (25 received placebo and 24 received AT-005). Most demographic factors were similar between the two groups, with the exception that more dogs with stage IV and V disease were treated with AT-005 (34% vs. 8%; p = 0.03). Median PFS was 103 days (95% confidence interval [CI], 56-118) in the placebo group versus 64 days (95% CI, 36-118) in the AT-005 group. The overall response rate (ORR) for all dogs was 98% (48 of 49); complete response rate in the placebo group (64%) was not different from the AT-005 group (67%).

Conclusions: To the best of the authors' knowledge, this is the first prospective study to document that treatment with L-CHOP chemotherapy, with or without AT-005, may result in a high ORR, but relatively brief PFS in dogs with clinical intermediate- and high-grade T-cell lymphoma.

PubMed Disclaimer

Conflict of interest statement

Chad Johannes, Laura Treml and Lydia Cook McAnulty are former employees of Aratana Therapeutics, Inc. and were employed by Aratana Therapeutics, Inc. during the study period. Elizabeth McNiel is a former employee of Elanco Animal Health. Chad Johannes, Craig Clifford and Philip Bergman are advisory board members for Elanco Animal Health and receive honoraria. Margaret Musser has not declared any conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Enrollment flow diagram
See this image and copyright information in PMC

References

    1. Moore AS. Treatment of T‐cell lymphoma in dogs. Vet Rec. 2016;179(11):277. - PubMed
    1. Vail D, Pinkerton M, Young K. Hematopoietic tumors. In: Vail D, Thamm D, Liptak J, editors. Withrow and MacEwen's small animal clinical oncology. 6th ed. St Louis, MO, USA: Elsevier Saunders; 2020. p. 688–772.
    1. Rebhun RB, Kent MS, Borrofka SA, Frazier S, Skorupski K, Rodriguez CO. CHOP chemotherapy for the treatment of canine multicentric T‐cell lymphoma. Vet Comp Oncol. 2011;9(1):38–44. - PubMed
    1. Angelo G, Cronin K, Keys D. Comparison of combination l‐asparaginase plus CHOP or modified MOPP treatment protocols in dogs with multi‐centric T‐cell or hypercalcaemic lymphoma. J Small Anim Pract. 2019;60(7):430–7. - PubMed
    1. Rassnick KM, Bailey DB, Malone EK, Intile JL, Kiselow MA, Flory AB, et al. Comparison between L‐CHOP and an L‐CHOP protocol with interposed treatments of CCNU and MOPP (L‐CHOP‐CCNU‐MOPP) for lymphoma in dogs. Vet Comp Oncol. 2010;8(4):243–53. - PubMed